Perrigo (PRGO) Co. and Actavis Plc (ACT) alone have added a combined $44 billion in market capitalization since announcing they were reincorporating abroad. The gains would make it easier for a larger rival to acquire them and meet the threshold for inversions that typically requires the foreign company’s investors to end up with at least 20 percent of the combined firm. Once Salix Pharmaceuticals Ltd. closes its deal with Cosmo Pharmaceuticals SpA and moves its mailbox to Ireland, it too could top the target list, said Canaccord Genuity Group Inc.
